{"nctId":"NCT00772109","briefTitle":"Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","startDateStruct":{"date":"2008-10"},"conditions":["Orthomyxoviridae Infection","Influenza","Myxovirus Infection"],"count":4292,"armGroups":[{"label":"Fluzone Intradermal Vaccine Lot 1","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza Virus Vaccine USP Trivalent Types A and B"]},{"label":"Fluzone Intradermal Vaccine Lot 2","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza Virus Vaccine USP Trivalent Types A and B"]},{"label":"Fluzone Intradermal Vaccine Lot 3","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza Virus Vaccine USP Trivalent Types A and B"]},{"label":"Fluzone Intramuscular Vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Influenza Virus Vaccine USP Trivalent Types A and B"]}],"interventions":[{"name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":[]},{"name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":[]},{"name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":[]},{"name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":["Fluzone®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Aged 18 to 64 years on the day of vaccination.\n* Informed consent form signed and dated.\n* Able to attend all scheduled visits and to comply with all trial procedures.\n* For women of child bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until at least 4 weeks after vaccination.\n\nExclusion Criteria :\n\n* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.\n* For a woman of child-bearing potential: known pregnancy or positive serum/urine pregnancy test.\n* Breast-feeding woman.\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the four weeks preceding the trial vaccination.\n* Planned participation in another clinical trial during the present trial period.\n* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy\n* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.\n* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures.\n* Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.\n* Receipt of any vaccination in the 4 weeks preceding the trial vaccination.\n* Planned receipt of any vaccine in the 4 weeks following the trial vaccination.\n* Previous vaccination against influenza in the past 6 months with the trial vaccine or another vaccine.\n* Thrombocytopenia or bleeding disorder in the 3 weeks preceding inclusion.\n* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.\n* Neoplastic disease or any hematologic malignancy, (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy, and subjects who have a history of neoplastic disease and who have been disease free for \\>=5 years).\n* Personal or family history of Guillain-Barré Syndrome.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines","description":"The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.50","spread":null},{"groupId":"OG001","value":"25.27","spread":null},{"groupId":"OG002","value":"25.29","spread":null},{"groupId":"OG003","value":"24.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188.56","spread":null},{"groupId":"OG001","value":"185.59","spread":null},{"groupId":"OG002","value":"206.10","spread":null},{"groupId":"OG003","value":"178.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.77","spread":null},{"groupId":"OG001","value":"20.56","spread":null},{"groupId":"OG002","value":"18.37","spread":null},{"groupId":"OG003","value":"19.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"260.46","spread":null},{"groupId":"OG001","value":"234.03","spread":null},{"groupId":"OG002","value":"246.06","spread":null},{"groupId":"OG003","value":"230.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.77","spread":null},{"groupId":"OG001","value":"25.59","spread":null},{"groupId":"OG002","value":"24.24","spread":null},{"groupId":"OG003","value":"25.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.72","spread":null},{"groupId":"OG001","value":"102.91","spread":null},{"groupId":"OG002","value":"100.82","spread":null},{"groupId":"OG003","value":"126.91","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Achieved Seroconversion Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine","description":"The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.\n\nSeroconversion was defined as either a pre-vaccination HAI titer \\< 1:10 and post-vaccination titer of ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum of four-fold increase 28 days post-vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"63","spread":null},{"groupId":"OG003","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Seroprotection Pre- and Post-vaccination With Either Fluzone ID or Fluzone IM","description":"The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.\n\nSeroprotection was defined as a HAI antibody titer ≥ 1:40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting a Solicited Injection Site or Systemic Reactions, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine","description":"Solicited injection site reactions: Ecchymosis, Erythema, Induration, Pain, Pruritus, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"716","spread":null},{"groupId":"OG001","value":"698","spread":null},{"groupId":"OG002","value":"726","spread":null},{"groupId":"OG003","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"120","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"554","spread":null},{"groupId":"OG001","value":"533","spread":null},{"groupId":"OG002","value":"547","spread":null},{"groupId":"OG003","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"480","spread":null},{"groupId":"OG001","value":"449","spread":null},{"groupId":"OG002","value":"500","spread":null},{"groupId":"OG003","value":"749","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"447","spread":null},{"groupId":"OG001","value":"430","spread":null},{"groupId":"OG002","value":"438","spread":null},{"groupId":"OG003","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"544","spread":null},{"groupId":"OG001","value":"525","spread":null},{"groupId":"OG002","value":"519","spread":null},{"groupId":"OG003","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":null},{"groupId":"OG001","value":"279","spread":null},{"groupId":"OG002","value":"314","spread":null},{"groupId":"OG003","value":"422","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"202","spread":null},{"groupId":"OG002","value":"239","spread":null},{"groupId":"OG003","value":"309","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":null},{"groupId":"OG001","value":"229","spread":null},{"groupId":"OG002","value":"260","spread":null},{"groupId":"OG003","value":"430","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":953},"commonTop":["Injection site erythema","Injection site pain","Injection site induration","Injection site swelling","Injection site pruritus"]}}}